<DOC>
	<DOCNO>NCT00778518</DOCNO>
	<brief_summary>Study find optimal dose Growth Hormone Replacement young adult patient suffer childhood onset growth hormone deficiency ( GHD ) .</brief_summary>
	<brief_title>Safety , Tolerability PK/PD Study Young Adult Patients With Childhood Onset Growth Hormone Deficiency ( GHD ) .</brief_title>
	<detailed_description>The primary objective study evaluate safety , tolerability pharmacodynamic response three different ARX201 dos ( PEG-ahGH ) administer repeatedly young adult patient childhood onset growth hormone deficiency ( GHD ) .</detailed_description>
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1830 year old GHD childhood onset complete growth IGF1 &lt; =2SDS rhGH treatment naive hGH level cutoff History malignancy intracranial tumor ECG abnormality ICH hepatic dysfunction renal impairment major medical condition inadequate T4 positive HBV , HCV , HIV alcohol drug abuse</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>growth hormone</keyword>
	<keyword>growth hormone deficiency</keyword>
	<keyword>GHD</keyword>
	<keyword>PEG</keyword>
	<keyword>pegylated</keyword>
	<keyword>IGF-1</keyword>
</DOC>